The firm last week announced it received funding that will allow it to complete development of the test, called Myelo-Scan, by the end of 2026.

Last week, readers were most interested in a story about whether digital pathology is approaching a breakout moment in its adoption curve.

Within three years, the project anticipates at least one test for the early-stage detection of Alzheimer's disease could be ready for commercialization.

The Cambridge, UK-based firm said that the project will help it to develop its breath-based tests and support the development of tools for breath-based testing.

NEW YORK – German digital pathology company Mindpeak announced Monday that it has raised $15.3 million in a Series A financing round.